Skip to main content
Premium Trial:

Request an Annual Quote

New York State Certifies GenetWorx to Perform Drug-Response Panel

NEW YORK (GenomeWeb) – GenetWorx said today that it has been certified by New York State to perform its drug-response genetic testing service on samples collected in the state.

The certification means Glen Allen, Va.-based GenetWorx is able to provide the test to patients in all 50 states in the US, it said. The lab is also CLIA certified.

Called the GenetWorx DNA Drug-Response Panel, the testing panel includes assays for drug metabolizing enzymes and cardiac disease risk factors. It examines a patient's genetic metabolizer type for several cytochrome 450 enzymes that activate many commonly prescribed cardiology, pain management, and psychiatry medications.

GenetWorx was founded in 2012 and provides DNA analysis for use by clinicians to support treatment decisions. In December 2013, its clinical lab received accreditation from the College of American Pathologists.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.